Iser Stephanie, Hintermair Sarah, Varga Alexander, Çelik Ali, Sayan Muhammet, Kankoç Aykut, Akyürek Nalan, Öğüt Betül, Bertoglio Pietro, Capozzi Enrico, Solli Piergiorgio, Ventura Luigi, Waller David, Weber Michael, Stubenberger Elisabeth, Ghanim Bahil
Karl Landsteiner University of Health Sciences, Dr. Karl-Dorrek-Straße 30, 3500 Krems, Austria.
Department of General and Thoracic Surgery, University Hospital Krems, Mitterweg 10, 3500 Krems, Austria.
Cancers (Basel). 2023 Dec 24;16(1):93. doi: 10.3390/cancers16010093.
Evoked from asbestos-induced inflammation, pleural mesothelioma represents a fatal diagnosis. Therapy ranges from nihilism to aggressive multimodality regimens. However, it is still unclear who ultimately benefits from which treatment. We aimed to re-challenge inflammatory-related biomarkers' prognostic value in times of modern immune-oncology and lung-sparing surgery. The biomarkers (leukocytes, hemoglobin, platelets, neutrophils, lymphocytes, monocytes, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), C-reactive protein (CRP)) and clinical characteristics (age, sex, histology, therapy) of 98 PM patients were correlated to overall survival (OS). The median OS was 19.4 months. Significant OS advantages (Log-Rank) were observed in multimodal treatment vs. others (26.1 vs. 7.2 months, < 0.001), surgery (pleurectomy/decortication) vs. no surgery (25.5 vs. 3.8 months, < 0.001), a high hemoglobin level (cut-off 12 g/dL, 15 vs. 24.2 months, = 0.021), a low platelet count (cut-off 280 G/L, 26.1 vs. 11.7 months, < 0.001), and a low PLR (cut-off 194.5, 25.5 vs. 12.3 months, = 0.023). Histology (epithelioid vs. non-epithelioid, = 0.002), surgery ( = 0.004), CRP (cut-off 1 mg/dL, = 0.039), and platelets ( = 0.025) were identified as independent prognostic variables for this cohort in multivariate analysis (Cox regression, covariates: age, sex, histology, stage, CRP, platelets). Our data verified the previously shown prognostic role of systemic inflammatory parameters in patients treated with lung-sparing surgery within multimodality therapy.
胸膜间皮瘤由石棉诱导的炎症引发，是一种致命的诊断结果。治疗方法从消极对待到积极的多模式治疗方案不等。然而，究竟谁能最终从哪种治疗中获益仍不明确。我们旨在重新审视在现代免疫肿瘤学和保肺手术时代，炎症相关生物标志物的预后价值。对98例胸膜间皮瘤患者的生物标志物（白细胞、血红蛋白、血小板、中性粒细胞、淋巴细胞、单核细胞、中性粒细胞与淋巴细胞比值（NLR）、淋巴细胞与单核细胞比值（LMR）、血小板与淋巴细胞比值（PLR）、C反应蛋白（CRP））和临床特征（年龄、性别、组织学、治疗方法）与总生存期（OS）进行相关性分析。中位总生存期为19.4个月。在多模式治疗与其他治疗（26.1个月对7.2个月，P<0.001）、手术（胸膜切除术/剥脱术）与非手术治疗（25.5个月对3.8个月，P<0.001）、高血红蛋白水平（临界值12 g/dL，15个月对24.2个月，P = 0.021）、低血小板计数（临界值280 G/L，26.1个月对11.7个月，P<0.001）以及低PLR（临界值194.5，2
